# Rare Foods Australia

RFA



16 May 2024

# Optimising a strong asset base

#### **NEED TO KNOW**

- Q3 sales weaker but expected to rebound
- Record processing to help meet forward order demand and lift utilisation and revenues
- Capital raise to optimise asset base

Weaker quarterly sales attributed to delay of large order for 8.8 tonnes of abalone which was pushed into April from March. Underlying sales of 14.6 tonnes contributed to \$0.7m sales revenue, taking YTD sales revenue to \$3.3m (vs our FY24 forecast of \$4.8m). We expect a strong rebound in Q4.

**Record processed volumes support strong orderbook**: processing facility throughput reached 98 tonnes YTD (+22% pcp) while harvest volumes of RFA's MSC greenlip abalone reached 62 tonnes YTD (+5% pcp). Sales and forward orders of 92 tonnes for FY24 represents 96% of total tonnage sold in FY23

**Secured \$2m from recent capital raise:** this included strong backing from existing major shareholders with proceeds to be directed towards repayment of debt, delivery of live abalone product, marketing of the Wine Reef trial, increased ocean signature wine production and additional working capital.

### **Investment Thesis**

**Through a growing global network of master distributors**, RFA is positioned to meet growing demand for sustainable high-end culinary offerings, including seafood, through its tiered offering of farmed, ranched and wild abalone.

RFA has Marine Stewardship Council (MSC) accreditation (blue fish tick) and is the only wild enhanced fishery globally that is using sustainable practices to commercially produce wild greenlip abalone. The company supplies more than 20% of global supply for wild greenlip abalone.

RFA holds the only two licensed ocean leases in WA which allow use of the ocean floor. Through its extensive R&D program, the company is learning to maximise biomass growth and yields by improving juvenile survival, which will lead to greater and more sustainable harvest volumes, from the same cost base, hence lifting margins.

### Valuation - base case of \$0.14 per share

Our base-case DCF valuation has been updated to A\$0.14 per share (from A\$0.33 previously). A conservative cross-check, removing growth from the Esperance Project still expected to be developed in the future, implies a valuation of A\$0.08. Key drivers of the change include updates to key assumptions including harvest volumes, higher cost of capital, increased share count and the timeline for new projects including Esperance.

#### **Risks**

**Changes to Esperance**: a large part of our base case valuation includes the Esperance development. We caveat this with our ex-Esperance valuation.

**Ability to raise capital:** to support growth initiatives, including the Esperance project, RFA will require external funding.

#### **Equity Research Australia**

Food, Beverage & Tobacco

Michael Youlden, Senior Analyst michael.youlden@mstaccess.com.au



Rare Foods Australia (RFA) grows wild greenlip abalone through an aquaculture technique known as 'sea ranching'. With this method, hatchery-bred juvenile abalone are placed in the ocean onto RFA-designed artificial reefs ('ABITATs') and left to nature to grow for 2–3 years until they reach a marketable size. The company has the competitive advantages of providing year-round supply to meet market demand and a method that offers proven sustainability.

Valuation **0.140** (from 0.330)

Current price 0.029

Market cap **A\$8.0m** 

Cash on hand ~A\$0.5m

#### **Additional Resources**

3Q update webinar

#### **Upcoming Catalysts / Next News**

Period									
Ongoing	Potential accretive growth initiatives								
July 2024	Quarterly update								
August 2024	FY result								

#### Share Price (\$A)



Source: FactSet, MST Access

Report prepared by MST Access, a registered business name of MST Financial services ABN 617 475 180 AFSL 500 557.

mstaccess.com.au

Figure 1: Financial summary (June year-end)

MARKET DATA							12 month share price performance	e					
Price	\$				0.029		0.09						
DCF Valuation	\$				0.14		0.08						
Totalreturn	%				383%		0.06	~~~	٠٨				
52 week high / low	\$			0.02	6-0.082		0.05		<b>└─</b> ─~^	L 100			
Market capitalisation	\$m				8.0		0.04			_~`V	2		
Shares on issue (ordinary)	m				269.2		0.02						
Options / rights	m				7.9		0.01						
Shares on issue (diluted)	m				277.1		0 — 10/5/23 19/7/23	27/9/23	6/12/23	14/2/24	24/4/24		
INVESTMENT FUNDAMENTALS		FY22A	FY23A	FY24E	FY25E	FY26E	PROFIT AND LOSS		FY22A	FY23A	FY24E	FY25E	FY26E
Reported NPAT	\$m	-0.9	-1.4	-1.0	-0.9	-0.4	Abalone Revenue	\$m	3.9	4.9	4.8	5.1	5.9
Underlying NPAT	\$m	-0.9	-1.4	-1.0	-0.9	-0.4	Total Income	\$m	6.0	7.6	7.8	8.2	8.9
<b>,.</b>	•						Operating Expenses	\$m	-7.3	-10.6	-10.2	-10.6	-11.3
Reported EPS (diluted)	¢	-0.4	-0.7	-0.4	-0.3	-0.2	EBITDA	\$m	-1.3	-3.1	-2.4	-2.5	-2.4
Underlying EPS (diluted)	¢	-0.4	-0.7	-0.4	-0.3	-0.2	Depreciation & amortisation	Śm	-0.6	-0.5	-0.4	-0.4	-0.3
Growth	%	nm	nm	nm	nm	nm	EBIT	\$m	-2.0	-3.6	-2.8	-2.8	-2.7
UnderlyingPER	x	nm	nm	nm	nm	nm	Net interest	Śm	0.0	-0.1	-0.1	0.0	0.0
, 0							Fair value adjustment on biomass	\$m	2.0	3.0	1.9	2.0	2.3
Operating cash flow per share	¢	-0.9	-0.3	-0.1	-0.1	0.1	Other non operating income	Śm	0.0	0.0	0.0	0.0	0.0
Free cash flow per share	¢	-1.2	-0.5	-0.1	-0.1	-7.9	PBT	\$m	0.0	-0.7	-1.0	-0.9	-0.4
Price to free cash flow per share	x	nm	nm	nm	nm	nm	Tax expense	Śm	-0.9	-0.8	0.0	0.0	0.0
FCF yield	%	-42.1%	-18.2%	-2.5%		-272.0%	Reported NPAT	\$m	-0.9	-1.4	-1.0	-0.9	-0.4
<b>,</b>							Adjustments to underlying	\$m	0.0	0.0	0.0	0.0	0.0
Dividend	¢	0.0	0.0	0.0	0.0	0.0	Underlying NPAT	\$m	-0.9	- <b>1.4</b>	-1.0	-0.9	-0.4
Payout	%	0%	0%	0.0	0%	0%	ygm Ai	<i>7</i> 111	3.3	71-7	1.0	0.5	0.7
Yield	%	0.0%	0.0%	0.0%	0.0%	0.0%	Weighted average shares	m	200.7	202.3	235.7	273.1	277.1
Franking	%	0.0%	0.0%	0.0%	0.0%	0.0%	Weighted average diluted shares	m	200.7	202.3	244.5	277.1	277.1
Tranking	70	070	070	070	0 /0	070	weighted average dituted shares		200.1	202.3	211.5	211.1	211.1
Enterprise value	\$m	7.9	7.0	7.5	8.1	13.9	GROWTH PROFILE		FY22A	FY23A	FY24E	FY25E	FY26E
EV/Sales	x	1.3	0.9	1.0	1.0	1.6	Total Revenue	%	20.4	26.4	3.7	4.2	9.5
EV/EBITDA	х	nm	nm	nm	nm	nm	EBITDA	%	nm	nm	nm	nm	nm
EV/EBIT	x	nm	nm	nm	nm	nm	EBIT	%	nm	nm	nm	nm	nm
Price to book (NAV)	х	0.4	0.4	0.5	0.5	0.2	Underlying NPAT	%	nm	nm	nm	nm	nm
Price to NTA	x	0.4	0.4	0.5	0.5	0.2	Underlying EPS	%	nm	nm	nm	nm	nm
							DPS	%	n/a	n/a	n/a	n/a	n/a
KEYRATIOS inclFV adjustment		FY22A	FY23A	FY24E	FY25E	FY26E							
Gross margin	%	37.4	7.8	27.6	29.6	31.0	BALANCE SHEET		FY22A	FY23A	FY24E	FY25E	FY26E
NPAT margin	%	nm	nm	nm	nm	nm	Cash	\$m	0.8	0.0	1.4	1.1	8.2
ROE	%	nm	nm	nm	nm	nm	Receivables	\$m	2.1	2.2	2.1	2.1	2.3
ROA	%	nm	nm	nm	nm	nm	Inventory	\$m	0.8	0.7	0.5	0.3	0.3
							Biological assets	\$m	7.6	8.4	8.3	8.3	8.0
Net tangible assets per share	¢	6.4	5.8	5.0	4.1	9.8	Property, plant & equip, ROUA	\$m	4.6	4.6	3.9	3.7	25.5
Book value per share	¢	8.2	8.2	7.2	6.0	16.3	Goodwill and intangibles	\$m	0.1	0.1	0.1	0.1	0.1
Net debt / (cash)	\$m	-0.1	1.1	-0.3	0.0	5.9	Other	\$m	0.5	0.6	0.6	0.6	0.6
nterestaver (18 /netinterest)			52.7			2,5206	Totalassets	\$m	16.5	16.6	16.9	16.3	45.1
Gearing (net debt / EBITDA)	Х	0.1	nm	0.1	nm	nm	Payables	\$m	0.8	1.0	1.2	1.3	1.4
Leverage (net debt / (net debt + equity	) x	0.0	0.1	0.0	0.0	0.2	Borrowings	\$m	0.7	1.1	1.1	1.1	14.1
							Other	\$m	2.0	2.7	2.6	2.5	2.5
DUPONT ANALYSIS		FY22A	FY23A	FY24E	FY25E	FY26E	Total liabilities	\$m	3.5	4.8	4.9	4.9	18.0
Net Profit Margin	%	nm	nm	nm	nm	nm	Net assets	\$m	13.0	11.8	12.0	11.4	27.2
		0.4	0.5	0.5	0.5	0.2	Equity	\$m	27.0	27.1	29.1	29.1	45.1
Asset Tumover	X	0.4				nm			140	-15.3		-17.7	-17.9
Asset Tumover Return on Assets	х %	nm	nm	nm	nm	111111	Retained earnings	\$m	-14.0	-15.5	-17.1	-11.1	
			nm 1.4	nm 1.4	nm 1.4	1.7	Retained earnings Minorities	\$m \$m	0.0	0.0	-17.1 0.0	0.0	0.0
Return on Assets	%	nm					•						0.0 <b>27.2</b>
Return on Assets Financial Leverage	% x	nm 1.3	1.4	1.4	1.4	1.7	Minorities	\$m	0.0	0.0	0.0	0.0	
Return on Assets Financial Leverage Return on Equity KEYPERFORMANCE INDICATORS	% x	nm 1.3	1.4	1.4 nm	1.4 nm	1.7	Minorities Shareholders' equity CASH FLOW	\$m	0.0 <b>13.0</b>	0.0 <b>11.8</b>	0.0	0.0 <b>11.4</b>	
Return on Assets Financial Leverage Return on Equity	% x	nm 1.3 <b>nm</b>	1.4 nm	1.4 nm	1.4 nm	1.7 nm	Minorities Shareholders' equity	\$m	0.0 <b>13.0</b>	0.0 <b>11.8</b>	0.0 <b>12.0</b>	0.0 <b>11.4</b>	27.2
Return on Assets Financial Leverage Return on Equity KEYPERFORMANCE INDICATORS	% × %	nm 1.3 nm	1.4 nm	1.4 nm	1.4 nm	1.7 nm	Minorities Shareholders' equity CASH FLOW	\$m <b>\$m</b>	0.0 <b>13.0</b> FY22A	0.0 <b>11.8</b> <b>FY23A</b>	0.0 <b>12.0</b> FY24E	0.0 <b>11.4</b> FY25E	27.2 FY26E
Return on Assets Financial Leverage Return on Equity  KEYPERFORMANCE INDICATORS Biological asset base	% × <b>%</b> T	nm 1.3 nm FY22A 203.4	1.4 nm FY23A 203.4	1.4 nm FY24E 199.0 8.4 11%	1.4 nm FY25E 194.3	1.7 nm FY26E 189.1	Minorities Shareholders' equity  CASH FLOW Net Income (Cashflow)	\$m <b>\$m</b> \$m	0.0 <b>13.0</b> FY22A -1.9	0.0 <b>11.8</b> FY23A -3.5	0.0 <b>12.0</b> FY24E -2.7	0.0 <b>11.4</b> FY25E -2.7	27.2 FY26E -2.6
Return on Assets Financial Leverage Return on Equity  KEYPERFORMANCE INDICATORS Biological asset base Biological asset base	% x % T \$m % T	nm 1.3 nm FY22A 203.4 7.6	1.4 nm FY23A 203.4 7.6	1.4 nm FY24E 199.0 8.4	1.4 nm FY25E 194.3 8.3	1.7 nm FY26E 189.1 8.3	Minorities Shareholders' equity  CASH FLOW Net Income (Cashflow) Depreciation & Amortization	\$m <b>\$m</b> \$m \$m	0.0 <b>13.0</b> FY22A -1.9 0.6	0.0 <b>11.8</b> FY23A -3.5 0.5	0.0 <b>12.0</b> FY24E -2.7 0.4	0.0 <b>11.4</b> FY25E -2.7 0.4	27.2 FY26E -2.6 0.3
Return on Assets Financial Leverage Return on Equity  KEYPERFORMANCE INDICATORS Biological asset base Biological asset base Growth	% x % T \$ m %	nm 1.3 nm FY22A 203.4 7.6 -24%	1.4 nm FY23A 203.4 7.6 0%	1.4 nm FY24E 199.0 8.4 11%	1.4 nm FY25E 194.3 8.3 -2%	1.7 nm FY26E 189.1 8.3 0%	Minorities Shareholders' equity  CASH FLOW Net Income (Cashflow) Depreciation & Amortization Change in Net Operating Assets	\$m <b>\$m</b> \$m \$m \$m	0.0 <b>13.0</b> FY22A -1.9 0.6 0.2	0.0 11.8 FY23A -3.5 0.5 2.1	0.0 12.0 FY24E -2.7 0.4 2.2	0.0 11.4 FY25E -2.7 0.4 2.1	27.2 FY26E -2.6 0.3 2.4 0.0
Return on Assets Financial Leverage Return on Equity  KEYPERFORMANCE INDICATORS Biological asset base Biological asset base Growth Harvest	% x % T \$m % T	nm 1.3 nm FY22A 203.4 7.6 -24% 81.7	1.4 nm FY23A 203.4 7.6 0% 81.0	1.4 nm FY24E 199.0 8.4 11% 82.0	1.4 nm FY25E 194.3 8.3 -2% 90.2	1.7 nm FY26E 189.1 8.3 0% 100.0	Minorities Shareholders' equity  CASH FLOW  Net Income (Cashflow)  Depreciation & Amortization Change in Net Operating Assets Other Non-Cash Items, Total	\$m \$m \$m \$m \$m \$m \$m	0.0 13.0 FY22A -1.9 0.6 0.2 -0.7	0.0 11.8 FY23A -3.5 0.5 2.1 0.3	0.0 12.0 FY24E -2.7 0.4 2.2 -0.1	0.0 11.4 FY25E -2.7 0.4 2.1 0.0	27.2 FY26E -2.6 0.3 2.4 0.0
Return on Assets Financial Leverage Return on Equity  KEYPERFORMANCE INDICATORS Biological asset base Biological asset base Growth Harvest Sales	% x % T T T	nm 1.3 nm FY22A 203.4 7.6 -24% 81.7 74.4	1.4 nm FY23A 203.4 7.6 0% 81.0 87.0	1.4 nm FY24E 199.0 8.4 11% 82.0 85.0	1.4 nm FY25E 194.3 8.3 -2% 90.2 88.4	1.7 nm FY26E 189.1 8.3 0% 100.0 98.0	Minorities Shareholders' equity  CASHFLOW Net Income (Cashflow) Depreciation & Amortization Change in Net Operating Assets Other Non-Cash Items, Total Operating cash flow	\$m \$m \$m \$m \$m \$m \$m	0.0 13.0 FY22A -1.9 0.6 0.2 -0.7 -1.8	0.0 11.8 FY23A -3.5 0.5 2.1 0.3 -0.6	0.0 12.0 FY24E -2.7 0.4 2.2 -0.1 -0.1	0.0 11.4 FY25E -2.7 0.4 2.1 0.0 -0.2	27.2 FY26E -2.6 0.3 2.4 0.0 0.2
Return on Assets Financial Leverage Return on Equity  KEYPERFORMANCE INDICATORS Biological asset base Biological asset base Growth Harvest Sales Sales Price, per KG	% x % T T T S	nm 1.3 nm FY22A 203.4 7.6 -24% 81.7 74.4 51.9	1.4 nm FY23A 203.4 7.6 0% 81.0 87.0 55.3	1.4 nm FY24E 199.0 8.4 11% 82.0 85.0 56.5	1.4 nm FY25E 194.3 8.3 -2% 90.2 88.4 58.2	1.7 nm FY26E 189.1 8.3 0% 100.0 98.0 59.9	Minorities Shareholders' equity  CASHFLOW Net Income (Cashflow) Depreciation & Amortization Change in Net Operating Assets Other Non-Cash Items, Total Operating cash flow Capital expenditure	\$m \$m \$m \$m \$m \$m \$m \$m	0.0 13.0 FY22A -1.9 0.6 0.2 -0.7 -1.8 -0.7	0.0 11.8 FY23A -3.5 0.5 2.1 0.3 -0.6 -0.6	0.0 12.0 FY24E -2.7 0.4 2.2 -0.1 -0.1	0.0 11.4 FY25E -2.7 0.4 2.1 0.0 -0.2 -0.1	27.2 FY26E -2.6 0.3 2.4 0.0 0.2 -22.0
Return on Assets Financial Leverage Return on Equity  KEYPERFORMANCE INDICATORS Biological asset base Biological asset base Growth Harvest Sales Sales Price, per KG Growth	% x % % T T S % %	nm 1.3 nm FY22A 203.4 7.6 -24% 81.7 74.4 51.9 -1%	1.4 nm FY23A 203.4 7.6 0% 81.0 87.0 55.3 6%	1.4 nm FY24E 199.0 8.4 11% 82.0 85.0 56.5 2%	1.4 nm  FY25E 194.3 8.3 -2% 90.2 88.4 58.2 3%	1.7 nm  FY26E  189.1  8.3  0%  100.0  98.0  59.9  3%	Minorities Shareholders' equity  CASHFLOW  Net Income (Cashflow) Depreciation & Amortization Change in Net Operating Assets Other Non-Cash Items, Total Operating cash flow Capital expenditure Acquisitions/divestment/other	\$m \$m \$m \$m \$m \$m \$m \$m \$m	0.0 13.0 FY22A -1.9 0.6 0.2 -0.7 -1.8 -0.7 0.0	0.0 11.8 FY23A -3.5 0.5 2.1 0.3 -0.6 -0.6	0.0 12.0 FY24E -2.7 0.4 2.2 -0.1 -0.1 0.0	0.0 11.4 FY25E -2.7 0.4 2.1 0.0 -0.2 -0.1 0.0	27.2 FY26E -2.6 0.3 2.4 0.0 0.2 -22.0
Return on Assets Financial Leverage Return on Equity  KEYPERFORMANCE INDICATORS Biological asset base Biological asset base Growth Harvest Sales Sales Price, per KG Growth Abalone revenue	% x % % T T S % \$m \$	nm 1.3 nm FY22A 203.4 7.6 -24% 81.7 74.4 51.9 -1% 3.9	1.4 nm  FY23A 203.4 7.6 0% 81.0 87.0 55.3 6% 4.9	1.4 nm  FY24E 199.0 8.4 11% 82.0 85.0 56.5 2% 4.8	1.4 nm  FY25E 194.3 8.3 -2% 90.2 88.4 58.2 3% 5.1	1.7 nm  FY26E  189.1  8.3  0%  100.0  98.0  59.9  3%  5.9	Minorities Shareholders' equity  CASHFLOW Net Income (Cashflow) Depreciation & Amortization Change in Net Operating Assets Other Non-Cash Items, Total Operating cash flow Capital expenditure Acquisitions/divestment/other Investing cash flow	\$m \$	0.0 13.0 FY22A -1.9 0.6 0.2 -0.7 -1.8 -0.7 0.0 -0.7	0.0 11.8 FY23A -3.5 0.5 2.1 0.3 -0.6 -0.6 0.0 -0.6	0.0 12.0 FY24E -2.7 0.4 2.2 -0.1 -0.1 0.0 -0.1	0.0 11.4 FY25E -2.7 0.4 2.1 0.0 -0.2 -0.1 0.0 -0.1	27.2 FY26E -2.6 0.3 2.4 0.0 0.2 -22.0 0.0
Return on Assets Financial Leverage Return on Equity  KEYPERFORMANCE INDICATORS Biological asset base Biological asset base Growth Harvest Sales Sales Price, per KG Growth Abalone revenue	% x % % T T S % \$m \$	nm 1.3 nm FY22A 203.4 7.6 -24% 81.7 74.4 51.9 -1% 3.9	1.4 nm  FY23A 203.4 7.6 0% 81.0 87.0 55.3 6% 4.9	1.4 nm  FY24E 199.0 8.4 11% 82.0 85.0 56.5 2% 4.8	1.4 nm  FY25E 194.3 8.3 -2% 90.2 88.4 58.2 3% 5.1	1.7 nm  FY26E  189.1  8.3  0%  100.0  98.0  59.9  3%  5.9	Minorities Shareholders' equity  CASH FLOW Net Income (Cashflow) Depreciation & Amortization Change in Net Operating Assets Other Non-Cash Items, Total Operating cash flow Capital expenditure Acquisitions/divestment/other Investing cash flow Equity	\$m \$	0.0 13.0 FY22A -1.9 0.6 0.2 -0.7 -1.8 -0.7 0.0 -0.7 0.0	0.0 11.8 FY23A -3.5 0.5 2.1 0.3 -0.6 -0.6 0.0 -0.6	0.0 12.0 FY24E -2.7 0.4 2.2 -0.1 -0.1 0.0 -0.1 2.0	0.0 11.4 FY25E -2.7 0.4 2.1 0.0 -0.2 -0.1 0.0 -0.1 0.0	<b>PY26E</b> -2.6 0.3 2.4 0.0 <b>0.2</b> -22.0 0.0 -22.0 16.0 13.0
Return on Assets Financial Leverage Return on Equity  KEYPERFORMANCE INDICATORS Biological asset base Biological asset base Growth Harvest Sales Sales Price, per KG Growth Abalone revenue	% x % % T T S % \$m \$	nm 1.3 nm FY22A 203.4 7.6 -24% 81.7 74.4 51.9 -1% 3.9	1.4 nm  FY23A 203.4 7.6 0% 81.0 87.0 55.3 6% 4.9	1.4 nm  FY24E 199.0 8.4 11% 82.0 85.0 56.5 2% 4.8	1.4 nm  FY25E 194.3 8.3 -2% 90.2 88.4 58.2 3% 5.1	1.7 nm  FY26E  189.1  8.3  0%  100.0  98.0  59.9  3%  5.9	Minorities Shareholders' equity  CASH FLOW Net Income (Cashflow) Depreciation & Amortization Change in Net Operating Assets Other Non-Cash Items, Total Operating cash flow Capital expenditure Acquisitions/divestment/other Investing cash flow Equity Increase / (decrease) in borrowing:	\$m \$m \$m \$m \$m \$m \$m \$m \$m \$m \$m \$m \$m \$	0.0 13.0 13.0 -1.9 0.6 0.2 -0.7 -1.8 -0.7 0.0 -0.7 0.0	0.0 11.8 FY23A -3.5 0.5 2.1 0.3 -0.6 -0.6 0.0 -0.6 0.0	0.0 12.0 FY24E -2.7 0.4 2.2 -0.1 -0.1 0.0 -0.1 2.0 0.0	0.0 11.4 FY25E -2.7 0.4 2.1 0.0 -0.2 -0.1 0.0 -0.1 0.0 0.0	<b>PY26E</b> -2.6 0.3 2.4 0.0 <b>0.2</b> -22.0 0.0 -22.0 16.0 13.0 0.0
Return on Assets Financial Leverage Return on Equity  KEYPERFORMANCE INDICATORS Biological asset base Biological asset base Growth Harvest Sales Sales Price, per KG Growth Abalone revenue	% x % % T T S % \$m \$	nm 1.3 nm FY22A 203.4 7.6 -24% 81.7 74.4 51.9 -1% 3.9	1.4 nm  FY23A 203.4 7.6 0% 81.0 87.0 55.3 6% 4.9	1.4 nm  FY24E 199.0 8.4 11% 82.0 85.0 56.5 2% 4.8	1.4 nm  FY25E 194.3 8.3 -2% 90.2 88.4 58.2 3% 5.1	1.7 nm  FY26E  189.1  8.3  0%  100.0  98.0  59.9  3%  5.9	Minorities  Shareholders' equity  CASH FLOW  Net Income (Cashflow) Depreciation & Amortization Change in Net Operating Assets Other Non-Cash Items, Total Operating cash flow Capital expenditure Acquisitions/divestment/other Investing cash flow Equity Increase / (decrease) in borrowing: Dividend/other	\$m \$m \$m \$m \$m \$m \$m \$m \$m \$m \$m \$m \$m \$	0.0 13.0 FY22A -1.9 0.6 0.2 -0.7 -1.8 -0.7 0.0 -0.7 0.0 0.7 -0.1	0.0 11.8 -3.5 0.5 2.1 0.3 -0.6 -0.6 0.0 -0.6 0.0	0.0 12.0 FY24E -2.7 0.4 2.2 -0.1 -0.1 -0.1 -0.0 0.0 0.0 -0.1	0.0 11.4 FY25E -2.7 0.4 2.1 0.0 -0.2 -0.1 0.0 0.0 -0.1	<b>PY26E</b> -2.6 0.3 2.4 0.0 <b>0.2</b> -22.0 0.0 -22.0 16.0 13.0 0.0 29.0
Return on Assets Financial Leverage Return on Equity  KEYPERFORMANCE INDICATORS Biological asset base Biological asset base Growth Harvest Sales Sales Price, per KG Growth Abalone revenue	% x % % T T S % \$m \$	nm 1.3 nm FY22A 203.4 7.6 -24% 81.7 74.4 51.9 -1% 3.9	1.4 nm  FY23A 203.4 7.6 0% 81.0 87.0 55.3 6% 4.9	1.4 nm  FY24E 199.0 8.4 11% 82.0 85.0 56.5 2% 4.8	1.4 nm  FY25E 194.3 8.3 -2% 90.2 88.4 58.2 3% 5.1	1.7 nm  FY26E  189.1  8.3  0%  100.0  98.0  59.9  3%  5.9	Minorities Shareholders' equity  CASH FLOW Net Income (Cashflow) Depreciation & Amortization Change in Net Operating Assets Other Non-Cash Items, Total Operating cash flow Capital expenditure Acquisitions/divestment/other Investing cash flow Equity Increase / (decrease) in borrowing: Dividend/other Financing cash flow	\$m \$m \$m \$m \$m \$m \$m \$m \$m \$m \$m \$m \$m \$	0.0 13.0 FY22A -1.9 0.6 0.2 -0.7 -1.8 -0.7 0.0 -0.7 0.0 0.7 -0.1 0.6	0.0 11.8 FY23A -3.5 0.5 2.1 0.3 -0.6 -0.6 0.0 -0.6 0.0 0.1 0.0 0.0	0.0 12.0 FY24E -2.7 0.4 2.2 -0.1 -0.1 -0.0 0.0 -0.1 1.9	0.0 11.4 FY25E -2.7 0.4 2.1 0.0 -0.2 -0.1 0.0 -0.1 -0.0 -0.1	27.2  FY26E  -2.6 0.3 2.4 0.0 0.2 -22.0 0.0 16.0 13.0 0.0 29.0 1.1
Return on Assets Financial Leverage Return on Equity  KEYPERFORMANCE INDICATORS Biological asset base Biological asset base Growth Harvest Sales Sales Price, per KG Growth Abalone revenue	% x % % T T S % \$m \$	nm 1.3 nm FY22A 203.4 7.6 -24% 81.7 74.4 51.9 -1% 3.9	1.4 nm  FY23A 203.4 7.6 0% 81.0 87.0 55.3 6% 4.9	1.4 nm  FY24E 199.0 8.4 11% 82.0 85.0 56.5 2% 4.8	1.4 nm  FY25E 194.3 8.3 -2% 90.2 88.4 58.2 3% 5.1	1.7 nm  FY26E  189.1  8.3  0%  100.0  98.0  59.9  3%  5.9	Minorities Shareholders' equity  CASHFLOW Net Income (Cashflow) Depreciation & Amortization Change in Net Operating Assets Other Non-Cash Items, Total Operating cash flow Capital expenditure Acquisitions/divestment/other Investing cash flow Equity Increase / (decrease) in borrowing: Dividend/other Financing cash flow Opening cash	\$m \$	0.0 13.0 FY22A -1.9 0.6 0.2 -0.7 -1.8 -0.7 0.0 -0.7 0.0 0.7 0.0 0.7 0.0 2.6	0.0 11.8 -3.5 0.5 2.1 0.3 -0.6 -0.6 0.0 -0.6 0.0 0.1 0.0 0.0	0.0 12.0 FY24E -2.7 0.4 2.2 -0.1 -0.1 -0.0 -0.1 2.0 0.0 0.0 1.9	0.0 11.4 FY25E -2.7 0.4 2.1 0.0 -0.2 -0.1 0.0 -0.1 -0.0 -0.1	<b>PY26E</b> -2.6 0.3 2.4 0.0 <b>0.2</b> -22.0 0.0 - <b>22.0</b> 16.0 13.0
Return on Assets Financial Leverage Return on Equity  KEYPERFORMANCE INDICATORS Biological asset base Biological asset base Growth Harvest Sales Sales Price, per KG Growth Abalone revenue	% x % T T S % \$m \$	nm 1.3 nm FY22A 203.4 7.6 -24% 81.7 74.4 51.9 -1% 3.9	1.4 nm  FY23A 203.4 7.6 0% 81.0 87.0 55.3 6% 4.9	1.4 nm  FY24E 199.0 8.4 11% 82.0 85.0 56.5 2% 4.8	1.4 nm  FY25E 194.3 8.3 -2% 90.2 88.4 58.2 3% 5.1	1.7 nm  FY26E  189.1  8.3  0%  100.0  98.0  59.9  3%  5.9	Minorities Shareholders' equity  CASHFLOW Net Income (Cashflow) Depreciation & Amortization Change in Net Operating Assets Other Non-Cash Items, Total Operating cash flow Capital expenditure Acquisitions/divestment/other Investing cash flow Equity Increase / (decrease) in borrowing: Dividend/other Financing cash flow Opening cash Net cash flow	\$m \$	0.0 13.0 FY22A -1.9 0.6 0.2 -0.7 -1.8 -0.7 0.0 -0.7 0.0 0.7 -0.1 0.6 2.6 -1.9	0.0 11.8 -3.5 0.5 2.1 0.3 -0.6 -0.6 0.0 -0.6 0.0 0.1 0.0 0.0 0.0 0.8 -1.1	0.0 12.0  FY24E -2.7 0.4 2.2 -0.1 -0.1 0.0 -0.1 2.0 0.0 -0.1 1.9 0.0 1.7	0.0 11.4 FY25E -2.7 0.4 2.1 0.0 -0.2 -0.1 0.0 -0.1 0.0 -0.1 1.4 -0.3	27.2  FY26E  -2.6 0.3 2.4 0.0 0.2 -22.0 0.0 -22.0 16.0 13.0 0.0 29.0 1.1 7.1

## 3Q24 Update

## Recent sales performance

RFA's core business sold 11.3 tonnes of Marine Stewardship Council (MSC) certified Greenlip abalone (ranched) during Q3, with total abalone sales reaching 14.6 tonnes across its multi-tier offering. This offering includes ranched Greenlip, wild caught Greenlip, Brownlip and Roei and farmed Greenlip abalone. The result excluded an 8.8 tonne order that was moved from March to April, due to a customer import timing issue, which would have taken told volume sold to 23.4 tonnes (vs 22 tonnes in Q2 and 24 tonnes in Q1).

Volumes sold contributed to sales revenue of \$0.7m during the guarter, taking YTD revenue to \$3.3m (relative to our latest forecast of \$4.8m for FY24; FY23 saw \$4.9m in sales revenue). Average YTD prices of abalone sold equate to \$54.2/kg, while MSC accredited ranched Greenlip averaged \$56.5/kg.

While the result was weaker QoQ, processing throughput has been significantly up 22% YTD (vs the same nine-month period in FY23), underpinned by a record 98 tonnes of abalone processed over the period. The forward order book for abalone product has remained strong, with sales and forward order demand reaching 92 tonnes, representing 96% of the total tonnage sold in FY23.

RFA remains the only fishery in the world using these innovative ranching processes to commercially produce Greenlip abalone, setting it apart in a market that increasingly values sustainability and wild harvest sourced products.




Figure 2: Quarterly RFA sales revenue (\$m)

Source: Company reports

As highlighted below, sales volumes decreased during the quarter while average sales price per kg remained relatively stable. We expect there to be a strong rebound in Q4, given the large order of 8.8 tonnes was rolled into April, from the previous expectation of March.




Figure 3: Quarterly RFA sales volume T (LHS) and average sales price / kg (RHS)

Source: Company reports

## Harvest and processing volumes

To support abalone product sales while balancing the need for biomass replenishment, 13 tonnes of ranched Greenlip abalone were harvested in Q3, down from 26.3 tonnes in Q2 and 22.8 tonnes in Q1. YTD harvested volumes now total 62 tonnes (+5% pcp).


Figure 4: Quarterly RFA ranched wild greenlip harvest volume (tonnes)



Source: Company data

31.2 tonnes of abalone products were processed during the quarter, which follows 39.6 tonnes in Q2 and 27.2 tonnes in Q1. This has led to a record of 98 tonnes of the tiered based abalone products processed YTD for the first three quarters of FY24 (+22% pcp). This includes abalone product sourced externally from other producers who pay RFA a processing fee to prepare the product for sale. We estimate approximately two thirds of abalone product that is processed is also produced and harvested by RFA, with the remainder from external third parties.

Figure 5: Quarterly processing volume of ranched wild greenlip, wild origin & farmed tonnes




Source: Company data

#### **Biomass valuation**

Following RFA's most recent biomass revaluation, the company recorded a 16% decline in the total biomass from 199 tonnes (FY23) to 166 tonnes (1H24). This was largely due to RFA's reduction of juvenile abalone deployment numbers to strategically conserve working capital during COVID in FY21 (once juveniles are deployed on the ranch, they take approximately three years to grow to harvestable size). Additionally, the decline in total biomass can be attributed to the relocation and reconditioning of 20% of the artificial reef (2k ABITATS) which commenced in the beginning of FY22 following strategic efforts to further enhance the growth productivity of the ocean ranch.

Figure 6: Ranched wild greenlip biomass value (\$m)



Source: Company data

Deployment improvement processes have continued over the past two years and culminated in the successful FY24 deployment of 1.2m juveniles, where was achieved ahead of schedule. This was completed across 11 deployment events, which represented 32% fewer events than averaged over previous years, reducing overall logistics costs. Improved deployment practices have also contributed to a significant increase (+26% equivalent to 847k more abalone) in juvenile numbers on the artificial reef according to RFA, which points to stronger production numbers beyond FY24. RFA continues to target annual harvest volume from its existing ocean ranch asset of 100-120 tonnes p.a. (vs 81 tonnes achieved in FY23 and similar estimated to be harvested in FY24).

### Continued R&D supports ABITAT productivity

Over the last 10 years, RFA has undertaken a detailed evaluation of ABITAT productivity alongside usual operational activities. This was reviewed in detail and strategies to improve productivity were finalised during Q3. The analysis reveals that ABITAT productivity gradually declines over time due to the accumulation of marine plants and animals (referred to as biofouling), impacting areas available for abalone growth on an ABITAT. As a result, a 7-Year Strategy to improve ranch productivity has been developed, with the aim of reducing biofouling and creating more space for higher rates of abalone survival and growth. Based on 10 years of production history, the harvest strategy estimates that a sustainable harvest level is between 100-120 tonnes p.a.

#### New seven-year ABITAT cycle

After seven years of harvests, ABITATs will be lifted to the surface, cleaned, returned to the seabed, and restocked. This will lead to ~1.4k ABITATs being refurbished each calendar year, with 10k ABITATs in circulation. The strategy is aimed at improving operational efficiency (including through higher rates of yield from harvested abalone which are larger in size) by up to 25% for the boat fleet and the dive team.

#### Other commercial outcomes

#### Premium retail offerings on site at the Ocean Pantry

Sales continued to grow at the Company's retail precinct, Ocean Pantry, achieving a record quarter of revenue of \$58k (vs \$50k reported in Q2). The Ocean Pantry is designed to promote the Company's abalone and ocean cellaring innovations through tours and tastings.

### **Ocean Cellaring**

Ocean Signature, the recently harvested product range from RFA's ocean cellaring activities obtained a liquor license in December 2023. During Q3, the Ocean Signature product range was harvested from the ocean floor, allowing sales of 2.3k bottles of wine to commence for both RFA, and strategic partners Glenarty Road and Edwards wineries. A further 2k bottles will be deployed during Q4, with 50% available for sale by RFA (as was the case with the allotment just harvested).

#### Additional HoA with Wine Reef International

Late last year in October, a formal Heads of Agreement was signed with Wine Reef International to begin a trial to ramp up ocean cellaring activities, targeting the production of an additional 13k bottles of ocean cellared product in FY24 in an initial six-month trial. Pre-deployment activities are now complete. Custom-designed Winereef vats have been delivered to Augusta, and wines have been chosen for the project. The vats allow the wine to age by constant movement from ocean swell and with pressure at depth, consistent temperature and low levels of light, all in a process that cannot be replicated on land. Diving activities have been organized and detailed, with third-party assistance secured for preparing, retrieving, and blending the vats. Deployment is planned for Q4 as well.

#### **Distributor Tours**

During the quarter, the company initiated strategies to assist Master Distributors in enhancing the promotion of tiered abalone products, which included hosting customer visits to its facilities. These visits aimed to assess the tiered abalone offerings, advance orders, and explore ways to reduce logistics costs. Notably, the company welcomed its largest Hong Kong Master Distributor during this period. This followed a visit by Vietnamese buyer MiGroup in Q2, where they toured the Augusta facility and experienced a showcase of wild caught abalone and ocean cellared products.

#### Live processing in Perth

A definitive holding and distribution agreement was established with Live Seafood Company, allowing for the processing of live abalone in Perth, further adding existing product lines to better meet the international demand for wild caught abalone products. The Live Seafood Company is tasked with receiving, settling, and purging live abalone, as well as preparing and packaging the product to complete customer orders before shipment to freight forwarders. RFA will pay a starting fee of \$7 per kg for these services. This agreement spans two years and includes biannual reviews aimed at enhancing processes, quality, and reducing costs.

#### **Esperance & other initiatives**

During the quarter, RFA and Yumbah finalised arrangements with local indigenous group Esperance Tjaltjraak Native Title Aboriginal Corporation (ETNATC) to secure the land opportunity to pursue the acquaculture precinct concept at Wylie Bay. The parties will now create the commercial agreements to plan and seek external funding to develop the precinct infrastructure and attract other acquaculture and marine related businesses to participate in the opportunity.

The Esperance project, which would add significant scale to RFA's abalone output, continues to be a part of the company's long term growth strategy, beyond the current core business. As previously mentioned, the project involves a new hatchery and farmed abalone site in nearby Esperance, WA. This could see an additional 300T pa net to RFA (50% interest), lowering the cost of juveniles and increasing margins through scale. Yumbah is a very credible partner, being the largest abalone aquaculture producer in Australia. We assume the cost of this project is \$40m net to RFA, funded with both debt and equity.

Separately, RFA has also continued the due diligence on exciting opportunities that could strengthen and scale the core business. Evaluation of these opportunities has been done on a confidential basis with due diligence expenditure to date of \$1.3m. RFA will update the market if and when binding arrangements are reached.

#### **Financials**

RFA recorded cash receipts of \$1.1m during the quarterly, down \$0.5m compared to Q2 primarily due to the 8.8 tonne March scheduled delivery being delayed to April. Net operating cash outflow was \$0.8m, taking YTD operating cash outflows to \$1.1m, with the major cost drivers during the quarter being wages (-\$1m, juvenile deployment payments of \$170k and legal/compliance fees of \$140k which cover reporting obligations and entitlement offer costs).

## **Funding**

During the quarter, RFA initiated a partially underwritten non-renounceable entitlement offer. This offer received strong backing from the Company's two largest shareholders, who contributed to a total raising of \$2 million (with a shortfall of an additional \$1m). Funds raised will be directed towards repayment of debt, delivery of live abalone product, marketing of the Wine Reef trial, increased ocean signature wine production and some additional working capital.

RFA is utilising its \$2.5m NAB credit facility and the support of a strong forward order book to ensure it can complete due diligence and associated activities to further scale and grow the business.

## Valuation

We have updated our DCF valuation to \$0.14 per share (from \$0.33 previously), which still implies upside from the current share price. Key drivers of the change include delayed timing of the Esperance project which we now assume will be commissioned in FY26, adjustments to the existing share count following the recent raise, an increase to our cost of capital assumption with the move higher in rates, and an adjustment to our outlook for harvest volumes for the existing core asset to reach 110 tonnes p.a. For the core business alone ex Esperance, our valuation is \$0.08 per share.

As at end March 2024, RFA has secured sales and forward order demand of 92 tonnes for wild caught greenlip for the FY24 annual period, equating to 96% of FY23 sales. We expect the sales mix to continue evolving, aided by RFA's MSC Accreditation and premiumisation strategy, which should continue to support average price growth from \$56.50/kg currently towards \$60.00/kg (FY22 pricing was \$51/kg). We now expect harvest volumes of wild grown greenlip abalone to reach 110 tonnes over the next two years (vs our previous forecast of up to 140 tonnes), which is the middle of the management's goal of 100-120 tonnes over the medium term. Sales revenue should also be supported by other tiered abalone products including farmed and wild abalone product, as well as distribution of new products including ocean cellared wine.

While RFA's existing 10-year agreement with 888 Abalone for the supply of farmed juveniles (1.2m per annum) approaches its formal completion date in June this year, we assume the existing arrangement will continue. With this, RFA stands to benefit from greater operating leverage as they continue to increase the survival rates and growth of wild grown abalone.

## Key assumptions of our DCF

- We assume that **prices** (and, in turn, **COGS**):
  - After rebounding strongly post the Covid period to ~\$56.50/kg, increase to \$60.00/kg by FY26 and 3% pa longer term as RFA benefits from its premiumisation strategy.
- We assume that harvested volumes:
  - increase to hit the middle of the company's target of 100-120T pa by FY27
  - increase beyond this with Esperance to beyond 400T pa by FY31
  - will largely offset growth in the biomass asset, keeping the underlying biomass value fairly constant.
- We assume that the business benefits from leverage at most cost lines (excluding employee
  costs rising between 3-5% pa and corporate costs rising 2% pa). Strong juvenile supply
  agreements at steady prices should allow the company to benefit from better pricing. We assume
  opex costs will experience a step change higher with more activity and volumes associated with the
  operating of the Esperance precinct.
- At present, we assume RFA's 50% share of the Esperance capital works (~\$40m) will be funded
  approximately with two thirds debt, and one third equity. For the equity component, we assume
  additional shares issued at the price equal to our underlying core asset valuation of \$0.08.
- Prior tax losses imply that RFA will not be paying tax for a considerable period. These tax losses include the non-cash item of fair value adjustment on the biological assets, which has accumulated +\$9.7m in FY15–FY22. Therefore, this tax loss underestimates the true cash loss.

## **Further Potential Valuation Upside**

We see further upside potential to our valuation. Factors that could potentially further lift our valuation include:

- Increased yield: achievable through lower mortality and higher productive growth rates, leading to greater harvest volumes
- Higher pricing: our forecast of \$56.50/kg in FY24, growing to \$60/kg by FY26, may be
  conservative given current bulk pricing as well as RFA's strategic move towards higher levels of
  retail sales
- · Higher sales volumes not only of abalone products but also ocean cellared wine products as well
- Increased utilisation and increased revenue from in-house processing plant: not only for in-house—sourced aquaculture but also for externally sourced product from third parties
- · Potential acquisitions, diversification and/or JV agreements

## Key Risks

- Aquaculture-related operational risks: these include the risks associated with safety of abalone diving, disease, theft, environmental changes, and severe weather events.
- **Incorrect biomass assessment:** given the assessment of biomass is carried out every 6 months using a sample, there is a risk the asset base is over or understated.
- Greenlip abalone prices and industry supply/demand dynamics: this can include additional
  unexpected supply domestically or offshore, through potential advanced technologies. It can
  include depressed demand from economic volatility or through government intervention with
  additional tariffs applied to the sector.
- Further changes to the Esperance Project: the Esperance project makes up \$A0.06 of our A\$0.14 valuation. Further delays due to extended labour shortages and other capex price increases may impact project expectations in the future.
- Long dated discounted cashflow valuations are highly dependent on long range forecasts and
  assumptions which can vary significantly over time. Key sensitivities for RFA include harvest and
  sales volumes, sales price achieved, biomass revaluations and timing and execution of long term
  growth plans associated with the Esperance project.
- Tariffs and other financial related risks: an increase in the Chinese/HK trade tariff on abalone could lead to weaker sales and prices, as occurred with lobster. Export abalone is also sold in US dollars, leading to additional foreign exchange risk.
- Partner relationships relating to various partnerships including Ocean King Fishing and Yumbah Aquaculture. Expansion plans depend on an effective relationship. There is also concentration risk associated with both suppliers and vendors given a degree of dependency.
- **Key management risk:** key management could be a risk if they departed the business and took with them their business relationships that may impact RFA.
- Funding: in order to successfully execute their growth plans, RFA will require external funding. The
  equity markets may be closed to RFA for a variety of reasons, in which case it may have to seek
  alternative options.

## Personal disclosures

Michael Youlden received assistance from the subject company or companies in preparing this research report. The company provided them with communication with senior management and information on the company and industry. As part of due diligence, they have independently and critically reviewed the assistance and information provided by the company to form the opinions expressed in this report. They have taken care to maintain honest and fair objectivity in writing this report and making the recommendation. Where MST Financial Services or its affiliates has been commissioned to prepare content and receives fees for its preparation, please note that NO part of the fee, compensation or employee remuneration paid has, or will, directly or indirectly impact the content provided in this report.

## Company disclosures

The companies and securities mentioned in this report, include:

Rare Foods Australia (RFA) | Price 0.029 | Valuation 0.140:

Price and valuation as at 16 May 2024 (\* not covered)

## Other disclosures, disclaimers and certificates

## Methodology & Disclosures

MST Access is a registered business name of MST Financial Services Limited (ABN 617 475 180 "MST Financial Services"), which is a limited liability company incorporated in Australia on 10 April 2017 and holds an Australian Financial Services Licence (AFSL 500 557). This research is issued in Australia through MST Access, which is the research division of MST Financial Services. The research and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by MST Access is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a financial product you should read any relevant Product Disclosure Statement or like instrument.

ECM and corporate advisory services: MST Financial Services provides equity capital markets ("ECM") and corporate advisory services through its capital markets division, MST Capital Markets ("MST Capital"). MST Capital provides these services to a range of companies including clients of MST Access. As such, MST Capital may in the future provide ECM and/or corporate advisory services and, accordingly, may receive fees from providing such services. However, MST Financial Services has measures in place to ensure the independence of its research division is maintained, including information barriers between its Capital Markets and Research teams. In addition, neither MST Access, nor any of its research analysts, receive any financial benefit that is based on the revenues generated by MST Capital or any other division of MST Financial Services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently certified. Opinions contained in this report represent those of MST Access at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results and estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of liability: To the fullest extent allowed by law, MST Access shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained in this report. No guarantees or warranties regarding accuracy, completeness or fitness for purpose are provided by MST Access, and under no circumstances will any of MST Financial Services' officers, representatives, associates or agents be liable for any loss or damage, whether direct, incidental or consequential, caused by reliance on or use of the content.

## General Advice Warning

MST Access Research may not be construed as personal advice or recommendation. MST Access encourages investors to seek independent financial advice regarding the suitability of investments for their individual circumstances and recommends that investments be independently evaluated. Investments involve risks and the value of any investment or income may go down as well as up. Investors may not get back the full amount invested. Past performance is not indicative of future performance. Estimates of future performance are based on assumptions that may not be realised. If provided, and unless otherwise stated, the closing price provided is that of the primary exchange for the issuer's securities or investments. The information contained within MST Access Research is published solely for information purposes and is not a solicitation or offer to buy or sell any financial instrument or participate in any trading or investment strategy. Analysis contained within MST Access Research publications is based upon publicly available information and may include numerous assumptions. Investors should be aware that different assumptions can and do result in materially different results.

MST Access Research is distributed only as may be permitted by law. It is not intended for distribution or use by any person or entity located in a jurisdiction where distribution, publication, availability or use would be prohibited. MST makes no claim that MST Access Research content may be lawfully viewed or accessed outside of Australia. Access to MST Access Research content may not be legal for certain persons and in certain jurisdictions. If you access this service or content from outside of Australia, you are responsible for compliance with the laws of your jurisdiction and/or the jurisdiction of the third party receiving such content. MST Access Research is provided to our clients through our proprietary research portal and distributed electronically by MST Financial Services to its MST Access clients. Some MST Access Research products may also be made available to its clients via third party vendors or distributed through alternative electronic means as a convenience. Such alternative distribution methods are at MST Financial Services' discretion

## Access & Use

Any access to or use of MST Access Research is subject to the <u>Terms and Conditions</u> of MST Access Research. By accessing or using MST Access Research you hereby agree to be bound by our Terms and Conditions and hereby consent to MST Financial Services collecting and using your personal data (including cookies) in accordance with our <u>Privacy</u>. <u>Policy</u>, including for the purpose of a) setting your preferences and b) collecting readership data so we may deliver an improved and personalised service to you. If you do not agree to our Terms and Conditions and/or if you do not wish to consent to MST Financial Services' use of your personal data, please do not access this service.

Copyright of the information contained within MST Access Research (including trademarks and service marks) are the property of their respective owners. MST Access Research, video interviews and other materials, or any portion thereof, may not be reprinted, reproduced, sold or redistributed without the prior written consent of MST Financial Services.